Myelofibrosis: State-of-the-Art Clinical Advances and Therapeutic Strategies From JAK Inhibition Into the Future

Learn strategies for selecting the optimal JAK inhibitor–based therapy from the experts to optimize the care of patients with myelofibrosis through an on-demand webcast with accompanying slides and a ClinicalThought commentary.

Share

Program Content

Activities

Initial Therapy for MF
Selecting Initial Treatment for Patients With Myelofibrosis
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2024

Expires: May 28, 2025

Novel Therapy for MF
A Look to the Future: Novel Agents and Combination Therapy for Myelofibrosis
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2024

Expires: May 28, 2025

Second Line Therapy for MF
Myelofibrosis Therapy in the Second Line and Beyond
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Activities

ASCO 2024 Myelofibrosis Roundtable
Myelofibrosis Expert Roundtable: State-of-the-Art Clinical Advances and Therapeutic Strategies From JAK Inhibition Into the Future
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2024

Expires: June 17, 2025

Faculty

cover img faculity

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Lucia Masarova, MD

Assistant Professor
Leukemia Department
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

cover img faculity

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline